%0 Journal Article
%A Koh, Gou Young
%A Augustin, Hellmut G
%A Campochiaro, Peter A
%T Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye.
%J Trends in molecular medicine
%V 28
%N 5
%@ 1471-4914
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2022-00705
%P 347-349
%D 2022
%Z DKFZ-ZMBH Alliance / 2022 May;28(5):347-349
%X Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35396185
%R 10.1016/j.molmed.2022.03.004
%U https://inrepo02.dkfz.de/record/179491